A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers

“…6 In another DDI study in patients with B-cell malignancies, co-administration of zanubrutinib with the CYP3A inhibitor fluconazole resulted in 1.81-fold and 1.88fold increases in zanubrutinib C max and AUC 0-24 h , respectively, and co-administration of zanubrutinib with the CYP3A inhibitor diltiazem resulted in a 1.62fold increase for both C max and AUC 0-24 h . 12 Although the reduction of zanubrutinib exposures with the coadministration of a strong CYP3A inducer such as rifampin has been evaluated, the magnitude and extent of reduction with the co-administration of less potent CYP3A inducers is largely unknown.…”